NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Regulation of Bone Formation in Renal Osteodystrophy
- Conditions
- Secondary HyperparathyroidismRenal Osteodystrophy
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2010-01-14
- Target Recruit Count
- 61
- Registration Number
- NCT00560300
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
- Conditions
- Stage I Thyroid Gland Papillary CarcinomaStage III Thyroid Gland Papillary CarcinomaStage IV Thyroid Gland Papillary CarcinomaStage II Thyroid Gland Papillary CarcinomaRecurrent Thyroid Gland Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00559949
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
- Conditions
- Stage IIIC Breast CancerStage IV Breast CancerMale Breast CancerProgesterone Receptor-negative Breast CancerRecurrent Breast CancerEstrogen Receptor-negative Breast CancerStage IIIB Breast Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00559507
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
- Conditions
- Stage IVA Cervical CancerCervical AdenocarcinomaStage IB Cervical CancerStage IIA Cervical CancerStage IIB Cervical CancerStage III Cervical CancerStage IVB Cervical CancerCervical Squamous Cell Carcinoma
- Interventions
- Other: 18F-fluoromisonidazoleRadiation: fluorodeoxyglucose F 18Procedure: positron emission tomographyOther: tissue oxygen measurement
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT00559377
- Locations
- 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China
- Conditions
- Lung CancerLeukemiaLymphomaBenzene PoisoningAcute Non-Lymphocytic Leukemia
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3260
- Registration Number
- NCT00559065
- Locations
- 🇨🇳
China Center for Disease Control (CDC), Beijing, China
Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium
- Conditions
- End Stage Renal Disease (ESRD)
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2860
- Registration Number
- NCT00559767
- Locations
- 🇺🇸
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States
Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment (Part 2)
- Conditions
- ObesityOverweight
- Interventions
- Behavioral: Standard Behavioral Weight Loss TreatmentBehavioral: Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training
- Locations
- 🇺🇸
The Weight Control and Diabetes Research Center, The Miriam Hospital, Providence, Rhode Island, United States
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
- Conditions
- HER2/Neu PositiveDuctal Breast Carcinoma In Situ
- Interventions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00555152
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
- Conditions
- Solid TumorsLymphomas
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00553189
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Recurrent Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT00553644
- Locations
- 🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
🇺🇸Kaiser Permanente-Bellflower, Bellflower, California, United States